CMP Teaching forum

3 reveals that the parties considered at length, but did not adopt, text which clearly required exclusivity for test data. Since the repression of "unfair competition" does not advocate any kind of exclusive rights nor the word "exclusivity" has been mentioned anywhere in the Article, the demand to give market exclusivity to pharmaceutical companies or the innovator on the basis of Article 39. Its high price rating keeps it in not reachable zone.

Review my webpage ... my latest blog post (how you can help)